- Gilead, Arcus’ updated TIGIT data unlikely to resolve debates around space: #ASCO23 Endpoints News
- Asco 2023 – Roche sees Morpheus and takes the red pill Evaluate Pharma
- ASCO: Gilead and Arcus’s Cancer Immunotherapy Combo Faces Scrutiny Over Lower Survival Rates BioSpace
- Gilead and Arcus’ TIGIT combo continues to show signs of life FierceBiotech
- Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study Business Wire
- View Full Coverage on Google News
Tag Archives: Endpoints
AstraZeneca: Tagrisso-chemo combo improved progression-free survival in late-stage lung cancer trial – Endpoints News – Endpoints News
- AstraZeneca: Tagrisso-chemo combo improved progression-free survival in late-stage lung cancer trial – Endpoints News Endpoints News
- AZ’s Tagrisso plus chemo triumphs in EGFR-mutated lung cancer FiercePharma
- Osimertinib and Chemotherapy Improves PFS in Advanced EGFRm NSCLC Targeted Oncology
- TAGRISSO® (osimertinib) plus chemotherapy demonstrated strong improvement in progression-free survival for patients with EGFR-mutated advanced lung cancer in FLAURA2 Phase III trial Business Wire
- Immunotherapy Plus Chemo Improves Quality of Life in NSCLC Medscape
- View Full Coverage on Google News
FDA approves Otsuka and Lundbeck’s schizophrenia, bipolar disorder injection – Endpoints News – Endpoints News
- FDA approves Otsuka and Lundbeck’s schizophrenia, bipolar disorder injection – Endpoints News Endpoints News
- FDA signs off on Otsuka and Lundbeck’s longer-acting Abilify FiercePharma
- FDA Approves Aripiprazole as First Once-Every-2-Months Long-Acting Injectable for Schizophrenia, Bipolar I Disorder Pharmacy Times
- NDA Approved for Long-Acting Injectable for Schizophrenia and Bipolar I Psychiatric Times
- FDA Approves Otsuka and Lundbeck’s ABILIFY ASIMTUFII® (aripiprazole), the First Once-Every-Two-Months Long-acting Injectable (LAI) for the Treatment of Schizophrenia or Maintenance Monotherapy Treatment of Bipolar I Disorder in Adults Business Wire
- View Full Coverage on Google News
Ginkgo snaps up gene therapy vector assets from StrideBio – Endpoints News
- Ginkgo snaps up gene therapy vector assets from StrideBio Endpoints News
- Ginkgo, hunting for biotech platforms that ‘collect dust,’ scoops up AAV gene therapy capsid specialist FierceBiotech
- Ginkgo Bioworks Strengthens End-to-End R&D Capabilities in Gene Therapy through Acquisition of StrideBio’s AAV Capsid Discovery and Engineering Platform Assets PR Newswire
- Sensible Biotechnologies Partners with Ginkgo to Develop Novel mRNA Manufacturing Platform Genetic Engineering & Biotechnology News
- Solvay, Gingko collaborate on sustainable biotechnology Food Business News
- View Full Coverage on Google News
Ginkgo sells Zymergen lab to chemical and material manufacturer Solvay – Endpoints News
- Ginkgo sells Zymergen lab to chemical and material manufacturer Solvay Endpoints News
- Sensible Biotechnologies And Ginkgo Bioworks Announce Partnership To Make In Vivo RNA To Unlock The Promise Of RNA Therapeutics Forbes
- Solvay Announces Strategic Collaboration With Ginkgo Bioworks And Expands Its R&I Footprint In The United States PR Newswire
- Sensible Biotechnologies Partners with Ginkgo to Develop Novel mRNA Manufacturing Platform Genetic Engineering & Biotechnology News
- Solvay, Gingko collaborate on sustainable biotechnology Food Business News
- View Full Coverage on Google News
89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks – Yahoo Finance
- 89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks Yahoo Finance
- Chasing Akero, 89bio reduces scarring in midphase NASH trial to hit primary goals, tee up phase 3 FierceBiotech
- ETNB Stock Rockets As It Takes On Akero In Fatty Liver Disease Investor’s Business Daily
- ETNB stock jumps on topline data for NASH candidate (NASDAQ:ETNB) Seeking Alpha
- 89bio’s stock rallies 48% on new NASH data MarketWatch
- View Full Coverage on Google News
What kind of PhIIb data is worth $4B cash? Takeda’s Andy Plump has some thoughts on that – Endpoints News
- What kind of PhIIb data is worth $4B cash? Takeda’s Andy Plump has some thoughts on that Endpoints News
- ‘We’ll look back and say that this was a bargain.’ Takeda reveals first data from its $4 billion autoimmune disease pill. The Boston Globe
- Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis businesswire.com
- Takeda’s $4 Billion Psoriasis Pill Helped Clear Skin in Mid-Stage Study Bloomberg
- Takeda raised to Buy at BofA on growth prospects and debt repayment (NYSE:TAK) Seeking Alpha
- View Full Coverage on Google News
Months after reorg, Adaptimmune merges with fellow cell therapy developer – Endpoints News
- Months after reorg, Adaptimmune merges with fellow cell therapy developer Endpoints News
- Adaptimmune and TCR² Therapeutics Announce Strategic Combination to Create a Preeminent Cell Therapy Company for Solid Tumors Yahoo Finance
- Adaptimmune sheds nearly 26% after strategic deal with TCR² Therapeutics (NASDAQ:ADAP) Seeking Alpha
- ADAP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Adaptimmune Therapeutics plc Is Fair to Shareholders Business Wire
- Adaptimmune absorbs TCR² to extend cash runway, broaden pipeline FierceBiotech
- View Full Coverage on Google News
FDA finally approves Reata’s rare genetic disease drug – Endpoints News
- FDA finally approves Reata’s rare genetic disease drug Endpoints News
- FDA Widens Path for Rare-Disease Treatments With New Approval The Wall Street Journal
- RETA Stock Skyrockets As FDA Approves Reata Phama’s Neurological Drug | Investor’s Business Daily Investor’s Business Daily
- Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omavaloxolone), the First and Only Drug Indicated for Patients with Friedreich’s Ataxia Business Wire
- FDA approves Reata’s treatment for rare neurological disease STAT
- View Full Coverage on Google News
The top 100 biotech VCs: Who’s staying at the table and what do they want now? – Endpoints News
- The top 100 biotech VCs: Who’s staying at the table and what do they want now? Endpoints News
- Aera Therapeutics Launches with $193 Million in Financing to Enable and Advance the Next Generation of Transformative Genetic Medicines businesswire.com
- Investors bet big on Feng Zhang’s new startup, out to solve one of gene editing’s most vexing problems The Boston Globe
- CRISPR pioneer Feng Zhang launches new genetic delivery startup with $193 million STAT
- Alnylam vet heads up new gene biotech with $193M in hand FierceBiotech
- View Full Coverage on Google News